Q-omics provides the consensus-scored RAB24 profile across patient tissues and cancer cell-line models. RAB24 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RAB24 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RAB24 protein abundance shows 25,023 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where RAB24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB24 survival associations across molecular data types. RAB24 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB24 RNA expression–survival associations across cancer types. High RAB24 expression shows unfavorable associations in LIHC, ACC, KICH, UVM and KIRP, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RAB24 RNA expression.
This table summarizes RAB24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB24 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, CHOL and KIRP. The KIRC box plot shows higher RAB24 RNA expression in tumor versus normal tissue (log2 FC = +1.475, t-test p < 0.001).
This table shows molecular features associated with RAB24 in patient tissues and cancer cell lines. In patient samples, RAB24 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
